Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies announced that its Compensation Committee granted stock options to three new employees on November 1, 2024. The options allow the purchase of 157,000 shares of common stock at $1.53 per share, matching the closing price on the grant date. These options were granted under the company's 2023 Inducement Plan, following Nasdaq Listing Rule 5635(c)(4). The options have a 10-year term and vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the following 36 months, subject to continued employment.
Taysha Gene Therapies ha annunciato che il suo Comitato per la Compensazione ha concesso opzioni su azioni a tre nuovi dipendenti il 1° novembre 2024. Le opzioni consentono l'acquisto di 157.000 azioni ordinarie a $1,53 per azione, corrispondente al prezzo di chiusura nel giorno della concessione. Queste opzioni sono state concesse nell'ambito del Piano di Induzione 2023 dell'azienda, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4). Le opzioni hanno un termine di 10 anni e maturano nell'arco di quattro anni, con il 25% che matura dopo un anno e il restante 75% che matura mensilmente nei successivi 36 mesi, soggetto a prosecuzione dell'impiego.
Taysha Gene Therapies anunció que su Comité de Compensación concedió opciones sobre acciones a tres nuevos empleados el 1 de noviembre de 2024. Las opciones permiten la compra de 157,000 acciones comunes a $1.53 por acción, coincidiendo con el precio de cierre en la fecha de concesión. Estas opciones se otorgaron bajo el Plan de Inducción 2023 de la compañía, de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq. Las opciones tienen un plazo de 10 años y se consolidan durante cuatro años, con un 25% consolidándose después de un año y el 75% restante consolidándose mensualmente durante los siguientes 36 meses, sujeto a la continuidad del empleo.
Taysha Gene Therapies는 보상 위원회가 2024년 11월 1일에 세 명의 신입 직원에게 주식 옵션을 부여했다고 발표했습니다. 이 옵션은 157,000주의 보통주를 주당 $1.53에 구매할 수 있도록 하며, 부여일의 종가와 일치합니다. 이 옵션은 회사의 2023 유도 계획에 따라 부여되었으며, 나스닥 상장 규칙 5635(c)(4)에 따릅니다. 이 옵션은 10년 만기이며 4년에 걸쳐 분할 배분되며, 1년 후에 25%가 배분되고 나머지 75%는 다음 36개월 동안 매달 배분됩니다. 이 조건은 계속 고용이 유지되는 경우에 해당합니다.
Taysha Gene Therapies a annoncé que son comité de rémunération avait accordé des options sur actions à trois nouveaux employés le 1er novembre 2024. Les options permettent l'achat de 157 000 actions ordinaires à 1,53 $ par action, correspondant au prix de clôture à la date d'octroi. Ces options ont été accordées dans le cadre du plan d'incitation 2023 de l'entreprise, conformément à la règle de cotation Nasdaq 5635(c)(4). Les options ont une durée de 10 ans et se libèrent sur quatre ans, avec 25 % se libérant après un an et les 75 % restants se libérant mensuellement sur les 36 mois suivants, sous réserve d'un emploi continu.
Taysha Gene Therapies gab bekannt, dass sein Vergütungsausschuss am 1. November 2024 Aktienoptionen an drei neue Mitarbeiter gewährt hat. Die Optionen erlauben den Kauf von 157.000 Aktien zu einem Preis von $1,53 pro Aktie, was dem Schlusskurs am Tag der Gewährung entspricht. Diese Optionen wurden im Rahmen des Induktionsplans 2023 des Unternehmens gewährt, in Übereinstimmung mit der Nasdaq-Listing-Regel 5635(c)(4). Die Optionen haben eine Laufzeit von 10 Jahren und unterliegen einer Vesting-Periode von vier Jahren, wobei 25% nach einem Jahr und die verbleibenden 75% monatlich über die folgenden 36 Monate vesten, vorbehaltlich einer fortdauernden Anstellung.
- Stock options align new employee interests with shareholder value
- Potential future dilution of existing shareholders through stock option grants
DALLAS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on November 1, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 157,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
FAQ
How many shares were granted in Taysha Gene Therapies (TSHA) November 2024 stock options?
What is the exercise price for TSHA's November 2024 stock option grant?
What is the vesting schedule for TSHA's November 2024 stock options?
